ArticleJournal of endocrinological investigation2026
Adrenal incidentalomas: 1 mg dexamethasone test result in the context of cardiometabolic risk.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMild autonomous cortisol secretion (MACS) is the most common hormonal abnormality in adrenal incidentalomas. The 1 mg dexamethasone suppression test (DST) with a cutoff of 1.8 µg/dL is used to exclude hypercortisolism, yet some "non-functioning" tumors may secrete cortisol at concentrations below this threshold, potentially contributing to an adverse cardiometabolic profile. The aim of this study was to evaluate this relationship.
methodsIn this retrospective cross-sectional study, data from 1,077 patients with adrenal incidentalomas treated at a tertiary endocrinology center between 2017 and 2020 were analyzed. After applying the inclusion criteria, 807 patients were included. All patients underwent a 1 mg DST. Receiver operating characteristic (ROC) curves and area under the curve (AUC) analyses were used to assess associations between post-DST cortisol concentrations and cardiometabolic conditions, and to identify a threshold for a composite endpoint comprising the presence of coronary heart disease, chronic heart failure, or diabetes mellitus.
resultsPatients with hypertension, coronary heart disease, heart failure, diabetes mellitus, chronic obstructive pulmonary disease, and chronic kidney disease had significantly higher post-DST cortisol concentrations. However, in multivariable logistic regression, post-DST cortisol was not independently associated with the composite endpoint after adjustment for confounders, with age and obesity remaining significant predictors. Exploratory analysis suggested that cortisol concentrations > 1.37 µg/dL were associated with a higher prevalence of the composite endpoint.
conclusionPost-DST cortisol concentrations below the standard cutoff may be associated with cardiometabolic comorbidities in patients with adrenal incidentalomas. These findings should be interpreted with caution and require confirmation in prospective studies.
Indexed as
Identifiers
42684648What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.